FindTrial
Sign In

CPI 613

DRUG4 trials

Sponsors

David Bajor, MD, University of Michigan Rogel Cancer Center, Wake Forest University Health Sciences

Conditions

Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in RelapseBiliary Tract CancerGranulocytic SarcomaNon Hodgkin LymphomaPancreatic CancerRefractory T-Cell LymphomaRelapsed T-Cell Lymphoma

Phase 1

CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
CompletedNCT03699319
David Bajor, MDPancreatic Cancer
Start: 2018-12-07End: 2024-09-23Updated: 2025-01-23
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
TerminatedNCT04203160
University of Michigan Rogel Cancer CenterBiliary Tract Cancer
Start: 2020-06-23End: 2024-04-29Updated: 2025-12-31

Phase 2

CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma
TerminatedNCT04217317
Wake Forest University Health SciencesNon Hodgkin Lymphoma, Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma
Start: 2020-09-16End: 2024-07-11Updated: 2025-05-02
CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
WithdrawnNCT05854966
Wake Forest University Health SciencesAcute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Granulocytic Sarcoma
Start: 2024-12-31End: 2025-09-30Updated: 2024-09-19

Related Papers

Phase 1b/2 results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- devimistat as first-line therapy for patients with advanced biliary tract cancer (BilT-04).
Journal of Clinical Oncology2024-06-012 citations
A phase I/II open-label clinical trial of CPI-613 in combination with modified FOLFIRINOX in patients with locally advanced (LAPC) or borderline resectable pancreatic cancer (BRPC).
Journal of Clinical Oncology2024-06-011 citations
Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinoma
BMJ Open2023-10-0111 citations
Phase 1b results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- CPI-613 as first-line therapy for patients with advanced biliary tract cancer (BilT-04).
Journal of Clinical Oncology2022-06-012 citations
Devimistat in Combination with Bendamustine Potently Inhibits Tumor Growth and Promotes CD8+ T Cell Tumor Infiltration in a Syngeneic Mouse Model of CD30+ T-Cell Lymphoma
Blood2021-11-05
A phase II open-label study of cpi-613 in combination with modified (m)FOLFIRINOX in patients with locally advanced pancreatic cancer.
Journal of Clinical Oncology2021-05-202 citations
A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-04).
Journal of Clinical Oncology2021-05-20